"Recent years have seen a decline in the use of retroviral vectors (currently, only 19.7% of trials compared to 22.8% in 2007 and 28% in 2004), presumably as a result of the severe adverse events observed in the SCID trials, and research is well underway towards engineering safer retroviral vectors. Adenoviruses are the most commonly used vector (23.3% of all trials)". From Ginn et al. The paper is free here https://www.researchgate.net/publication/235377142_Gene_therapy_clinical_trials_worldwide_to_2012_-_an_update?ev=srch_pub&_sg=0kuhTM7mdLSNcFCqpave%2FFokSjoKfCqUx9VdoVkGPAWfIEy7DFjp5kbHzyu%2FpGhb_jzpfkQaU5PeZB%2BeoH9jOl1WlWGKNjNlSFAKkpgkUNilM5BJ1aywW0EBQ8ILj9MK6_mDsIAWi7Xxzsd6Y36DXmPnoUj5SJWLJbllPLzZZ7C97CwrMe4%2Bukb1G%2Ba%2FYE%2FpZL
Article Gene therapy clinical trials worldwide to 2012 – An update
In cancer gene therapy AAVs have bene successfully used, being superior to other vectors for weak toxicity and long term gene expression. Have a look at this review
Best regards stefania
Article Adeno-Associated Virus-Mediated Cancer Gene Therapy: Current Status
I agree with both of you Bernardino Isaac Cerda-Cristerna
and Stefania Squadrone
Thanks for providing us with valuable links
my answer in : http://www.garlandscience.com/res/pdf/9780815341505_ch02.pdf
Manar,
Actually it depends on which disease and cell type you are working on. Some vectors are better in cancer, while other types are superior in cardovascular diseases.
However, it wouldn't be surprising to find Adenovirus, AAV, retrovirus, lentivirus, baculovirus etc. are the most common viral vectors in gene therapy.
Good luck
Manar, Vectors based on adeno-associated viruses (AAVs) have emerged as safe and effective and, in one recent case, have led to regulatory approval. In cancer gene therapy AAVs have bene successfully used.
http://www.ncbi.nlm.nih.gov/pubmed/24840552
As far as I know Adino associated viruses (AAVs) and lentiviruses are commonly used for gene therapy.
- Badges
- Science topic
- Similar topics
- Correction